Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)

BACKGROUND: The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing....

Descripción completa

Detalles Bibliográficos
Autores principales: Klamroth, Robert, Feistritzer, Clemens, Friedrich, Ute, Lentz, Steven R., Reichwald, Kirsten, Zak, Marek, Chowdary, Pratima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027501/
https://www.ncbi.nlm.nih.gov/pubmed/31618804
http://dx.doi.org/10.1111/jth.14660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027501/
https://www.ncbi.nlm.nih.gov/pubmed/31618804
http://dx.doi.org/10.1111/jth.14660

Ejemplares similares